INTRODUCTION
A diverse group of plasma membrane glycoproteins are attached to the cell surface by a glycosylphosphatidylinositol (GPI) tail, including enzymes, cell-adhesion molecules, and signaltransducing receptors (for recent reviews see refs. [1] [2] [3] [4] [5] [6] ). The role of this type of anchoring is not known. Several suggestions have been put forward for the function of GPI on glycoproteins, such as enhancement of lateral mobility of the glycoprotein in the lipid bilayer, sorting signalling for the transport to the apical plasma membrane in polarized cells, and involvement in signal transduction in the cell. An additional possible role is to permit selective release of glycoproteins from the cell surface by the action of GPI-specific phospholipases, thereby regulating the expression of certain glycoproteins on the surface. For such a role to be operative, the susceptibility for cleavage has to be restricted to glycoproteins on certain cells at a given time.
A GPI-specific phospholipase D (GPI-PLD) has been identified in sera from various species [7, 8] , and subsequently isolated and characterized [9] [10] [11] [12] [13] . When assayed in vitro, this phospholipase is only active against glycosylated phosphatidylinositol, and is so only in the presence of detergents. High levels of GPI-PLD are normally present in circulation, yet most GPI-anchored glycoproteins on blood cells and on the endothelium are resistant to cleavage. Furthermore, in experiments with cultured cells and liposomes, GPI-anchored glycoproteins are not released after the addition of serum or purified GPI-PLD to the medium [14] . This suggests either that the phospholipase has to be activated (mediated by detergent in the assays), or that the substrate (GPIcontaining protein) has to be correctly presented to the phospholipase, in order for cleavage to occur. In either case, such a mechanism would allow for a specific regulation of the release of GPI-anchored proteins to meet the needs of the cells.
In the present study, we have investigated the effects on GPI-PLD-mediated release of the GPI-anchored glycoprotein Thy-I Thy-I occurred under these conditions. From experiments with reconstituted liposomes it was inferred that the effect of saponin on cells was to aid in the presentation of Thy-I to GPI-PLD. Furthermore, it was concluded that cholesterol-saponin complexes formed in the membrane were not alone responsible for the effect. Rather, additional molecules in the plasma membrane are possibly involved in the presentation of Thy-i on saponintreated cells. This finding may have implications for a physiological role of circulating GPI-PLD in the regulation of GPIanchored proteins on cells.
[15] from a mouse T lymphoma cell line, by changing the membrane structure with saponin. Saponins are amphiphilic molecules, isolated mainly from plants, which were classically identified by their haemolytic activity (reviewed in [16] ). Saponins are known to be incorporated into lipid bilayers without solubilizing lipids or membrane proteins, and are therefore not classified as detergents. The haemolytic effect is caused by the generation of pores in the membrane, which is the result of complex formation with cholesterol [17] [18] [19] . The results in the present paper show that, upon treatment of cells with saponin, Thy-I in the membrane becomes susceptible to cleavage by GPI-PLD. Experiments using liposomes indicate that the positive effect of saponin is due to alteration of the membrane structure, and not to a stimulation of the enzyme. Furthermore, conditions favourable for saponin-mediated GPI-PLD cleavage could not be mimicked by cholesterol/phosphatidylcholine-containing liposomes. This finding raises the possibility that endogenous substances may exist in cells that regulate the presentation of GPI-anchored proteins for circulating GPI-PLD.
MATERIALS AND METHODS Assay of GPI-PLD
The substrate for GPI-PLD was prepared by iodination of Thy-1 purified from human brain [20] [23] , and 125I-Thy-l was eluted from gel pieces in 0.5 % Nonidet P-40. This stock solution of substrate was stored in the refrigerator for up to 2 weeks, and was used in the assay after a 25-fold dilution in D-buffer (50 mM Tris/HCl, 10 mM NaCl, 5 mM CaCl2, pH 7.4), giving a final concentration in the assay of 0.01 % Nonidet P-40 and traces of SDS (from the polyacrylamide gel).
Samples to be measured were diluted to 50,ul with D-buffer and mixed with 50 1l of substrate (10-20 nCi) in Eppendorf tubes. After incubation for 30 min at 37°C, the reaction was stopped by the addition of 800,1 of 1O mM EDTA in PBS (137 mM NaCl, 3 mM KCI, 8 mM Na2HPO4, 1.5 mM KH2PO4, pH 7.4). A 1:1 suspension (100 ,1) of phenyl-Sepharose (Pharmacia-LKB) in PBS was added and the tubes were incubated by end-to-end rotation for 30 min at room temperature. After a brief centrifugation (10000 g for 30 s), 800 ,ul of the supernatants was counted in the y-counter. Blank samples contained 501ul of D-buffer and 50,1 of substrate, and were treated identically to GPI-PLD-containing samples.
The percentage hydrolysis was calculated by dividing the radioactivity ofthe sample supernatant by (0.8 x the radioactivity added to each tube). The radioactivity of the blank supernatant (containing about 10 % of the added radioactivity) was subtracted from the samples to give percentage specific hydrolysis. A milliunit of GPI-PLD activity was defined as the activity giving 20 % specific hydrolysis in the assay. This assay is referred to as the 'GPI-PLD assay' in this paper.
PurMfcation of GPI-PLD and productlon of antibodies GPI-PLD was purified to homogeneity from fresh human plasma, from which plasminogen had been removed for other purposes. The details of the purification procedure will be described elsewhere. Briefly, after removal of fibrinogen by clotting, the serum was purified by chromatography on DEAE-Sephacel at pH 6.0, phenyl-Sepharose, DEAE-Sephacel at pH 8.0, and gel filtration on a Sephacryl S-300 column (all matrices were obtained from Pharmacia-LKB). The purification was followed by the GPI-PLD assay described above and by SDS/PAGE [23] . The GPI-PLD activity was enriched approx. 6000-fold. N-terminalsequence analysis revealed a single amino acid in each cycle and showed identity to a previously reported N-terminal sequence of human GPI-PLD [13] . The purified enzyme was stored at -20°C in 50 % (v/v) glycerol/10 mM Tris/HCl/75 mM NaCl, pH 7.4. Antiserum was produced by immunizing a rabbit with purified GPI-PLD, using a procedure described before [20] . IgG was purified on a protein A-Sepharose column (Pharmacia-LKB). GPI-PLD-free serum was prepared by incubating fresh human serum with rabbit anti-(human GPI-PLD) IgG coupled to Sepharose. The absence of GPI-PLD activity was confirmed by the GPI-PLD assay. 10 x 107 c.p.m.) was added serum, GPI-PLD, or phosphatidylinositol phospholipase C (Bacillus cereus, Boehringer-Mannheim) (PLC), all diluted in H-buffer, and the volume was adjusted to 100 jul with H-buffer. The-concentration of saponin described in the experiments refers to the final concentration obtained after adjustment to 100 j1. PLC activity was used as defined by the supplier. The cells were incubated for 1 h at 37 0C with gentle agitation and centrifuged at 4°C for 5 min at 350 g, and the supernatant was collected. The supernatant was re-centrifuged twice for 10 min at 10000g.
Thy-I was immunoprecipitated from the supernatants using a previously described procedure [25] , with the exception that protein A-Sepharose was used instead of Pansorbin cells to collect immune complexes. Rabbit anti-(mouse Thy-i) serum (15 jul) [24] was added to each supernatant and the mixture was incubated overnight. Immunoprecipitated material was analysed by SDS/PAGE (12.5 % acrylamide), and the gels were treated for fluorography with Enlightning (Du Pont) and exposed to Hyperfilm MP (Amersham). Radioactive Thy-I was quantified by scintillation counting after treatment of gel pieces with Solvable (Du Pont), as described elsewhere [25] .
The pool of Thy-I on the surface of Y191 cells that was susceptible to cleavage with PLC was found to be approx. 7000, which is consistent with results from other cells [26, 27] .
Triton X-114 partitioning Phase separation of amphiphilic and hydrophilic molecules was performed with pre-condensed Triton X-114 as described by Bordier [28] . After three cycles of partitioning, Thy-i was immunoprecipitated from the detergent phase and the water phase as described above.
To ensure that no cleavage of Thy-I occurred during the phase separation, a control experiment was performed in which fresh serum (final concentration 2 GPI-PLD units/ml) was added to 125I-labelled amphiphilic Thy-I in 20% (w/v) Triton X-1 14. No hydrophilic Thy-I was generated during the subsequent partitioning. Experiments with the GPI-PLD assay showed that the enzyme is completely inhibited in high concentrations of Triton X-114.
Liposome experiments Liposomes were made by the method of Brunner et al. [29] . Phosphatidylcholine (30 mg) (egg yolk, type V-E, Sigma Chemical Co.) was dissolved in ethanol/chloroform (1:1, v/v) and dried as a film together with 37.5 mg of sodium cholate (Larodan Fine Chemicals). In some experiments 40 mg of cholesterol (Larodan Fine Chemicals) was included. After two cycles of dissolving in ethanol and drying, the mixture was dissolved in 1 ml of L-buffer (10 mM Tris/HCl, 100 mM NaCl, pH 7.3). After brief centrifugation (15OOg for 5 min), 50-100 ng of 125I-Thy-I (approx. 5 x 0I c.p.m.) was added to the supernatant. The solution was applied to a column (20 x 0.8 cm) of Sephadex G-50 medium (Pharmacia-LKB), equilibrated with L-buffer, and was eluted with a flow rate of 2 ml/h. Formed liposomes with incorporated 1251-Thy-I were obtained in the void volume. In order to isolate small liposomes, the void volume eluate from the Sephadex G-50 column was gel-filtered on a column (25 cm x 1 cm) of Sepharose 4B (Pharmacia-LKB), equilibrated with L-buffer, at a flow rate of 6 ml/h. A homogeneous peak of radioactivity, which was eluted after a minor void volume peak, was collected and used in further experiments. Liposomes were stored at 4°C and used within 3 weeks.
Phosphatidylcholine content was determined by the method of
Release of Thy-1 by glycosylphosphatidylinositol-specific phospholipase D Steward as described in ref. [30] . Cholesterol was determined using a test kit manufactured by Boehringer-Mannheim. In liposomes containing both phosphatidylcholine and cholesterol, the molar ratio obtained was 2: 1. Liposomes (450 ,tg of total lipid) were treated with saponin in L-buffer containing 5 mM CaCl2 for 30 min on ice in a total volume of 355 ,ul. After addition of PLC, GPI-PLD, or serum, and adjustment of the volume to 374,ul, the mixture was incubated for 1 h at 37 'C. EDTA (40 ,u; 0.1 M) was added and the samples were immediately analysed by gel filtration on columns (25 cm x 1 cm) of Sephacryl S-300 (Pharmacia-LKB), equilibrated with L-buffer. The flow rate was 12 ml/h, and fractions (1 ml) were collected and counted for radioactivity. The columns were regenerated by washing with 1 % Nonidet P-40 and re-equilibrated with L-buffer.
Control experiments showed that hydrophilic 125I-Thy-I (released by PLC) was fully recovered (yield > 95 %) during gel filtration, whereas the yield of liposome-bound 1251-Thy-I was 60-80 %. Therefore, for the calculation of percentage hydrolysed '25I-Thy-1, the material in fractions corresponding to hydrophilic 125I-Thy-I (fractions 13-19, see Figure Sb ) was compared with the radioactivity applied to the column.
To determine the fraction of 1251-Thy-I that was located on the outside of the liposomes, excess Pronase digestions (10 ,ug/ml Pronase in L-buffer containing 5 mM CaCl2, for 1 h at 37 'C) were performed and the material was analysed by gel filtration as above. Pronase-digested radioactive material was eluted in fractions 20-30.
RESULTS
Measurement of enzyme activity and analysis of purffied GPI-PLD and antibodies For the determination of GPI-PLD activity in serum and during purification of the enzyme, an assay was developed based on the conversion of purified amphiphilic Thy-I into a form lacking the GPI structure. Samples to be measured were incubated together with 1251-labelled Thy-I in detergent, and the generated hydrophilic 1251-Thy-I was determined after adsorbing any uncleaved substrate to phenyl-Sepharose. The response was linear up to the point where approx. 30% of the substrate was hydrolysed (Figure la) . The activity resulting in 20 % specific hydrolysis in 30 rmn at 37 'C was defined as I m-unit. Fresh human serum samples showed activities of 30-70 units/ml. Analysis of generated hydrophilic 125I-Thy-l by SDS/PAGE and autoradiography showed a mobility indistinguishable from that of uncleaved Thy-I (results not shown). This is consistent with previous reports showing that removal of the GPI anchor from Thy-i does not influence its migration in SDS/PAGE [27] . The result also shows that the generation of radioactive hydrophilic product was not due to proteolytic fragmentation.
GPI-PLD was purified from human plasma by a series of chromatography steps, yielding a uniform band of apparent molecular mass 120 kDa when analysed by SDS/PAGE (Figure lb) . N-terminal sequence analysis gave a single amino acid derivative in each cycle, indicating that a homogeneous protein was obtained. Of ten identified amino acids, nine were identical to the N-terminal sequence of bovine serum GPI-PLD, derived from the cDNA sequence [12] , confirming the relationship between the two enzymes. The sequence also showed identity to a recently published N-terminal sequence of human GPI-PLD [13] .
Antibodies were produced by immunizing a rabbit with purified GPI-PLD. The antibodies were found to react predominantly with conformation-dependent epitopes, as treatment of the enzyme with SDS irreversibly destroyed the reactivity (results not shown). When tested on native GPI-PLD in serum, the antibodies effectively inhibited the enzyme activity (Figure ic) . This result shows that the only activity in serum capable of generating hydrophilic Thy-l, under the conditions used in the assay, is GPI-PLD. Complete inhibition was obtained at 20-100-fold excess (mol/mol) of IgG over GPI-PLD.
GPI-PLD-medlated release of Thy-1 after treatment of cells with saponin The cell line used in the present study was a mouse T-cell lymphoma, designated Y191, which in a previous study was shown to express large amounts of Thy-I on the cell surface [24] .
[3H]Ethanolamine, which is biosynthetically incorporated into the GPI moiety, was used to label Thy-1. By this means, a label was achieved that is retained in Thy-i after cleavage of the hydrophobic tail, and at the same time a low background in subsequent immunoprecipitations was obtained.
When labelled cells were incubated together with purified GPI- Figures 2a and 2b ). When cells were treated with saponin (0.2 mg/ml), most Thy-l was retained in the membrane and could be pelleted by centrifugation, leaving only small amounts in the supernatant (Figure 2b, lane 2) . However, when GPI-PLD was added to saponin-treated cells, efficient hydrolysis of Thy-l was achieved (Figure 2b , lanes 3-7, and Figure 2c , circles). Control experiments with Triton X-1 14 phase partitioning [28] showed that the effect was due to a true cleavage reaction, and not the result of solubilization. Conversely, the small amount of Thy-l appearing in the supernatant without enzyme present ( Figure 2b , lane 2) behaved as native (GPI-containing) Thy-l in phase partitioning (results not shown). The GPI-PLD activity required to release most of the PLC-releasable Thy-l was significantly higher than that required for GPI hydrolysis in the GPI-PLD assay where detergent is present. Nevertheless, hydrolysis of Thy-l on saponin-treated cells occurred with GPI-PLD activities far less than that present in serum (approx. 50 units/ml). Maximal hydrolysis was obtained at approx. 5 units/ml, and addition of higher enzyme activities did not result in further release (see lanes 6 and 7, Figure 2b ).
To test for the dependence of saponin concentration on the GPI-PLD-mediated hydrolysis, cells were incubated with increasing concentrations of saponin to which was added GPI-PLD at a fixed concentration (1 unit/ml) (Figure 3 at the highest concentration tested (I mg/ml) (closed triangles in Figure 3 ). This finding indicates that the two processes are not directly correlated.
To confirm that the effect of saponin was specific, and not due to a general 'detergent effect' on the membrane, the same experiment as shown in Figure 3 was performed with Nonidet P-40 instead of saponin. At concentrations where low levels of solubilization was obtained ( < 0.5 mg/ml), no stimulatory effect on GPI-PLD-mediated hydrolysis was detected with Nonidet P-40 (results not shown).
Effect of addition of serum to saponin-treated cells
Experiments were performed to see if the results with purified GPI-PLD were also reproducible with crude serum as the source of enzyme (Figure 4a ). The addition of serum to untreated cells gave no release of Thy-I (closed triangles in Figure 4a ). With saponin-treated cells (0.2 mg/ml saponin) (closed circles in Figure  4a ), release was achieved with an optimum at a serum dilution of 1: 50 (1 unit/ml GPI-PLD activity as measured in the GPI-PLD assay). At higher concentrations of serum the response was decreased. The reason for this serum-dependent decrease of Thy-I release at high serum concentrations is not known, but may be due to the possibility that the effective concentration of saponin is lowered as the result of binding to components in serum, such as lipoproteins.
The possibility that activities in serum other than GPI-PLD are able to release Thy-I from saponin-treated cells was ruled out by the experiment shown in Figure 4 (b). When serum was pre-treated with antibodies against purified GPI-PLD, the release was totally abolished. This experiment shows that GPI-PLD is the only enzyme in serum responsible for the release of Thy-I from saponin-treated cells.
Liposome experiments
The results presented so far show that saponin has a stimulatory effect on the hydrolysis of GPI-anchored Thy-I on the plasma membrane. This outcome could be mediated by different possible mechanisms. The effect could be at the enzyme level, where saponin either directly stimulates the activity of GPI-PLD, or removes an inhibiting substance. In the GPI-PLD assay, Nonidet P-40 would perform the same role. Alternatively, the effects of saponin could be at the substrate level. In this case, saponin could either assist in the presentation of the substrate for the enzyme, or relieve the inhibition caused by a blocking component in the membrane. Some of these possibilities can be tested by saponin-and GPI-PLD-treatment of reconstituted artificial liposomes with defined lipid composition.
Liposomes with incorporated 125I-Thy-I were treated in various ways and the release of Thy-I was determined by gel filtration, which separates liposome-bound radioactivity from hydrophilic released radioactivity ( Figure 5 ). Untreated phosphatidylcholine liposomes eluted as a homogeneous peak in or near the void volume of the column (fractions 8-10, Figure  5a ). Cleavage with PLC ( Figure Sb) resulted in an additional peak (fractions 14-16) representing released 1251-Thy-1. Taking into account that not all of the 1251-Thy-I was located on the outside of the liposomes (see legend to Table 1), it could be calculated that approx. 70% of exposed Thy-I was cleaved by PLC. This is in agreement with previous results on the susceptibility of Thy-i to PLC hydrolysis [27] . GPI-PLD treatment of liposomes resulted in minute amounts of hydrophilic Thy-I being generated (Figure 5c ). The extent of hydrolysis by GPI-PLD was not increased by pretreatment of liposomes with saponin ( Figure 5d ). Taken together, these results clearly indicate Samples were analysed by gel-filtration chromatography on columns of Sephacryl S-300 and eluted fractions were counted for radioactivity. Table 1 Phospholipase cleavage of liposome-bound 1'll-Thy-1
Liposomes containing 1251-Thy-1 were made from phosphatidylcholine (PC), or from a mixture of PC and cholesterol (PC/CH). Liposomes were incubated with or without saponin, serum and purified phospholipase, as described in the Materials and methods section. The samples were analysed by gel filtration chromatography on Sephacryl S-300 as shown in Figure 5 . Hydrolysis was calculated as the amount of radioactivity which was eluted in fractions 13-19, relative to total Pronase-accessible radioactivity applied to the column. * GPI-PLD-free serum was added to a protein concentration corresponding to active serum at 1.0 units/ml. that saponin does not act at the level of enzyme stimulation or removal of inhibition, as GPI-PLD is fully active under the same conditions as shown in Figure 5 (d) when added to cells (see Figure 2c) .
The probable mechanism for the effects of saponin is that it interferes with the structure of the plasma membrane in cells, resulting in a presentation of Thy-I which is favourable for GPI-PLD hydrolysis. If this is true, one has to postulate that other components in the membrane are also participating in this process, as saponin treatment of phosphatidylcholine liposomes gave no effect. An obvious candidate for this is cholesterol, which is known to bind saponin in cell membranes [18] . Liposomes were made containing phospholipid and cholesterol in a proportion comparable with that of plasma membranes [32] , into which was incorporated 125I-Thy-l. However, GPI-PLD was not able to hydrolyse Thy-I to any significant extent, neither on intact liposomes (Figure 5e ) nor on saponin-treated liposomes ( Figure Sf) . Therefore, other components in cell membranes may be important for saponin-mediated GPI-PLD hydrolysis of Thy-i.
In Table 1 Although saponins are not found in higher organisms, and can therefore not be physiological regulators of GPI-anchored protein presentation, the elucidation of the mechanism by which saponin exerts its effect in vitro may give some hints to a possible regulatory mechanism that is normally operating. Saponins are known to preferentially bind and sequester cholesterol in membranes, but binding to cholesterol-free membranes has also been detected [33] . However, from the results with liposomes in the present study, the conclusion can be drawn that saponincholesterol complexes are not alone responsible for the susceptibility of Thy-l to GPI-PLD. Other components in plasma membranes are likely to be important for correct presentation of the substrate. The nature of these components is completely unknown.
The resistance of GPI-anchored proteins in membranes to GPI-PLD hydrolysis is reminiscent of the situation for other phospholipases acting on membranes. The best-studied example is that of phospholipase A2, where crystal-structure determinations have pointed to a possible mechanism of action on the phospholipid membrane [34, 35] . In this case the substrate (phospholipid) seems to be drawn partly out of the membrane surface into the active site of the enzyme. It may be envisioned that GPI-PLD is using a similar mechanism to 'reach' its substrate, and that components in the membrane can stimulate or hamper this process.
Evidence from several recent studies has suggested that GPIanchored proteins are clustered in microdomains rich in glycosphingolipids and cholesterol (reviewed in [36] ). These microdomains are often associated with uncoated invaginations, called caveolae, which are involved in the uptake of small substances into cells [6] . The maintenance of both GPI-containing protein clusters and caveolae depends on the presence of cholesterol in the membrane. Depletion of cholesterol, either by the addition of cholesterol-binding substances (saponins and polyene macrolide antibiotics) or by growth of cells in the presence of an inhibitor of sterol synthesis, caused a dispersal of GPIanchored proteins on the membrane [37, 38] . This finding implies that the clustering of GPI-anchored proteins is controlled by lipid-lipid interactions between the fatty alkyl/acyl chains of the GPI anchor and the surrounding lipids in the bilayer. This phenomenon can be directly related to the susceptibility of GPIanchored proteins to GPI-PLD.
We have also tested a cholesterol-binding polyene macrolide, nystatin, for effects on GPI-PLD release of Thy-1. This substance, tested at concentrations up to 0.4 mg/ml, had no influence on the susceptibility of the GPI-anchored protein to the enzyme (results not shown). Even though both saponins and macrolides disperse GPI-anchored proteins in the membrane [37] , the mechanism of action may be different (e.g. affecting other molecules than cholesterol differently) due to their dissimilar structures. Further studies are required to investigate the role of cholesterol and other molecules in microdomains in more detail.
In order for GPI-PLD-mediated cleavage of a GPI-anchored protein to occur, it is possible that the GPI-containing protein has to be dispersed on the membrane and allowed to interact with (a) lipid or protein component(s) that facilitate the presentation to GPI-PLD. This presentation, which could be mediated by glycosphingolipids, may promote the accessibility of the substrate, perhaps in a process similar to that described for phospholipase A2. When normal concentrations of cholesterol are present, tight clustering occurs, which hampers the presentation. Removal of cholesterol by saponin (or by some unknown endogenous molecule in vivo) would disrupt the cluster in such a way that the GPI-anchored protein becomes susceptible to cleavage. This model would explain why artificial liposomes are poor at presenting GPI-anchored proteins, both in the absence and presence of cholesterol and saponin. It will be interesting to see if certain components in membranes can be identified that, when incorporated into liposomes, can promote the cleavage of GPI-anchored proteins by GPI-PLD.
